A more recent study modified PA by attachment to a single-chain variable fragment antibody to preferentially target pancreatic cancers that overexpress EGFR or the carcinoembryonic antigen (CEA). The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.